RxDoctor Payments Data

Dylan Allen, MD

Internal Medicine · Claremore, OKNPI 1336762202

Payments from drug & device makers

$1,359in general payments, 2019–2025

Across 73 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$406
  • Pfizer$159
  • GSK$108
  • AstraZeneca$101
  • Sumitomo Pharma America, Inc.$93
  • AbbVie$89
  • plus $403 from 10 others

What the payments were for

  • Food & beverage$1,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,359 in reported general payments places this provider in the 70th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$5,460
Medicare patients
27
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin89$92,615
EliquisApixaban89$78,319
MounjaroTirzepatide37$40,672
RybelsusSemaglutide20$29,517
FarxigaDapagliflozin Propanediol17$16,092
OzempicSemaglutide17$15,126
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,093
LantusInsulin Glargine,hum.Rec.Anlog23$3,005
Duloxetine Hcl53$2,822
Atorvastatin Calcium196$2,087
Levemir FlexpenInsulin Detemir12$1,823
Allopurinol28$1,669
Omeprazole85$1,552
Tamsulosin Hcl79$1,528
Gabapentin91$1,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$78,31989 claims
Novo NordiskRybelsus, Ozempic$406$44,64237 claims
Lilly USA, LLCMounjaro$69$40,67237 claims
AstraZenecaFarxiga$101$16,09217 claims
GSKTrelegy Ellipta$108$11,09311 claims
Sanofi-aventis U.S. LLCLantus$22$3,00523 claims
AbbVieSynthroid$89$1,35318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Claremore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →